METHODS: Flow cytometry was performed to analyze B, T, and natural killer (NK) cells in the peripheral blood (PB) of 45 CRC patients. Consecutively, lymphocytes in PB, tumor-infiltrating lymphocytes (TILs), and CD56+ and CD57+ lymphocytes at the invasion front and the tumor center were compared between patients with SARIFA-positive and SARIFA-negative CRCs.
RESULTS: Whereas no differences could be observed regarding most PB lymphocyte populations as well as TILs, NK cells were dramatically reduced in the PB of SARIFA-positive cases. Moreover, CD56 and CD57 immunohistochemistry suggested SARIFA-status-dependent changes regarding NK cells and NK-like lymphocytes in the tumor microenvironment.
CONCLUSIONS: This study proves that our newly introduced biomarker, SARIFA, comes along with distinct immunologic alterations, especially regarding NK cells.
方法:流式细胞术分析B,T,45例CRC患者外周血中的自然杀伤(NK)细胞。连续,PB中的淋巴细胞,肿瘤浸润淋巴细胞(TIL),比较了SARIFA阳性和SARIFA阴性CRCs患者在浸润前沿和肿瘤中心的CD56和CD57淋巴细胞。
结果:尽管在大多数PB淋巴细胞群体和TIL方面没有观察到差异,在SARIFA阳性病例的PB中,NK细胞显著减少。此外,CD56和CD57免疫组织化学提示肿瘤微环境中NK细胞和NK样淋巴细胞的SARIFA状态依赖性变化。
结论:这项研究证明了我们新引入的生物标志物,SARIFA,伴随着不同的免疫学改变,尤其是NK细胞。